4.7 Article

The VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells

Journal

CARDIOVASCULAR RESEARCH
Volume 118, Issue 2, Pages 622-637

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvab042

Keywords

von Willebrand factor; Smooth muscle cells; Vascular biology; Haemostasis; Proliferation

Funding

  1. Investments for the Future program [ANR-15-RHU-0004]
  2. Agence Nationale de la Recherche [ANR-13-BSV1-0026]
  3. Region Grand Est
  4. Fonds europe en de developpement regional
  5. Agence Nationale de la Recherche (ANR) [ANR-13-BSV1-0026] Funding Source: Agence Nationale de la Recherche (ANR)

Ask authors/readers for more resources

VWF induces VSMC proliferation through A2 domain binding to LRP4 receptor and integrin alpha(v)beta(3) signaling. These findings provide new insights into the mechanisms that drive physiological repair and pathological hyperplasia of the arterial vessel wall.
Aims Von Willebrand factor (VWF) is a plasma glycoprotein involved in primary haemostasis, while also having additional roles beyond haemostasis namely in cancer, inflammation, angiogenesis, and potentially in vascular smooth muscle cell (VSMC) proliferation. Here, we addressed how VWF modulates VSMC proliferation and investigated the underlying molecular pathways and the in vivo pathophysiological relevance. Methods and results VWF induced proliferation of human aortic VSMCs and also promoted VSMC migration. Treatment of cells with a siRNA against alpha(v) integrin or the RGT-peptide blocking alpha(v)beta(3) signalling abolished proliferation. However, VWF did not bind to alpha(v)beta(3) on VSMCs through its RGD-motif. Rather, we identified the VWF A2 domain as the region mediating binding to the cells. We hypothesized the involvement of a member of the LDL-related receptor protein (LRP) family due to their known ability to act as co-receptors. Using the universal LRP-inhibitor receptor-associated protein, we confirmed LRP-mediated VSMC proliferation. siRNA experiments and confocal fluorescence microscopy identified LRP4 as the VWF-counterreceptor on VSMCs. Also co-localization between alpha(v)beta(3) and LRP4 was observed via proximity ligation analysis and immuno-precipitation experiments. The pathophysiological relevance of our data was supported by VWF-deficient mice having significantly reduced hyperplasia in carotid artery ligation and artery femoral denudation models. In wild-type mice, infiltration of VWF in intimal regions enriched in proliferating VSMCs was found. Interestingly, also analysis of human atherosclerotic lesions showed abundant VWF accumulation in VSMC-proliferating rich intimal areas. Conclusion VWF mediates VSMC proliferation through a mechanism involving A2 domain binding to the LRP4 receptor and integrin alpha(v)beta(3) signalling. Our findings provide new insights into the mechanisms that drive physiological repair and pathological hyperplasia of the arterial vessel wall. In addition, the VWF/LRP4-axis may represent a novel therapeutic target to modulate VSMC proliferation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available